Depression Clinical Trial
Official title:
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Verified date | March 2012 |
Source | Cedars-Sinai Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a 12-week, double-blind, placebo-controlled study on the efficacy, tolerability and
safety of oral ziprasidone as monotherapy in patients with (major depressive disorder) MDD.
The study involves the enrollment of a total of 120 patients with MDD over the course of 12
months across two sites. Outpatients suffering from MDD will be treated with either
ziprasidone or with placebo for 12 weeks using the sequential parallel comparison design.
In light of the challenge major depressive disorder (MDD) poses to clinicians and patients
alike, identifying novel treatments is urgently needed to help further refine the standard
of care. Judging by their molecular structure and function, the atypical neuroleptic agents
offer possibilities as effective antidepressants. To date, several studies have been
reported examining the use of atypical neuroleptic agents as adjunctive therapy (used along
with an antidepressant) for MDD. These studies go so far as to suggest that atypical
neuroleptic agents have potential for treating MDD. Until now, atypical neuroleptics have
been strictly viewed as adjuncts, however, it is quite possible that some of the atypical
neuroleptic agents may possess antidepressant properties when used as the lone therapy.
The atypical neuroleptic agent ziprasidone, in particular, is an excellent neuroleptic
candidate for studying antipsychotic effects on MDD for two principal reasons: its structure
makes it favorable for binding to neurotransmitters in the brain and it has fewer
side-effects compared to the other drugs in its class. This study will be the first, double
blind, placebo-controlled trial of ziprasidone as monotherapy for MDD. If safe and effective
as an antidepressant, ziprasidone would represent an additional option for patients with
MDD.
Potential subjects will be approached during a regularly scheduled clinic visit, upon
referral from another physician, or in response to research advertisements. Interested
individuals will have the opportunity to review the consent form with family, friends, and
other physicians prior to making a final decision regarding study enrollment. Once the
subject has given informed consent, the screening process for the study will commence.
Subjects will have a screening visit to determine eligibility. The screening visit consists
of a medical evaluation, completion of psychological rating scales, physical/neurological
exams, electrocardiogram, and the collection of blood and urine. After subjects pass
screening, they will be randomized into one of 3 study groups. Subjects will receive either
12 weeks of ziprasidone, 12 weeks of placebo, or 6 weeks of placebo followed by 6 weeks of
ziprasidone. Study participants will have a 5 in 8 chance of receiving ziprasidone at some
point in the study.
Subjects will be closely monitored during the study via 2 phone calls weekly from the study
coordinator. The overall safety of the study will also be well scrutinized. The
investigators shall identify an independent physician safety monitor, who will be without
any affiliation to this study. He/she will be provided all the information necessary to
evaluate the study's safety parameters and whether or not they are effective preventative
measures.
Various psychological assessments will be completed by research subjects at every study
visit.
This research study is designed to test the safety and/or effectiveness of the
investigational use of the drug Ziprasidone that has been approved by the U.S Food and Drug
Administration (FDA). While the drug used in the study is FDA-approved for treating
schizophrenia and Bipolar disorder I, it is not yet approved for alleviating solely the
symptoms of depression.
Status | Completed |
Enrollment | 61 |
Est. completion date | December 2011 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Aged 18-65. 2. Written informed consent. 3. MDD, current according to the fourth version of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) as diagnosed by the Mini International Neuropsychiatric Interview. 4. Quick Inventory of Depressive Symptomatology - Self-Rated score of at least 10 at both screen and baseline visits. Exclusion Criteria: 1. Pregnant women. 2. Women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or a partner with vasectomy). 3. Treatment with antidepressants for 2 weeks prior to the study. 4. Patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to baseline. 5. Serious suicide or homicide risk, as assessed by the evaluating clinician or a score of 4 on the third item of the HAM-D. 6. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease. 7. Patients who meet criteria for alcohol or substance dependence, active within the last month. 8. Any bipolar disorder (current or past). 9. Any psychotic disorder (current or past). 10. Psychotic features in the current episode or a history of psychotic features. 11. History of a seizure disorder. 12. Clinical or laboratory evidence of untreated hypothyroidism. 13. Patients requiring excluded medications. 14. Prior course of ziprasidone, or intolerance to ziprasidone at any dose. 15. Any investigational psychotropic drug within the last 3 months. 16. Patients with significant cardiac conduction problems on screening electrocardiogram such as atrial fibrillation, atrial flutter, atrio-ventricular block, prolonged or abnormal QTc interval, or prolonged QRS interval. 17. Patients who have suffered a myocardial infarction within the past 12 months, with uncompensated heart failure, or a history of QTc prolongation. 18. Patients with abnormal serum potassium or magnesium levels upon screening. 19. Patients currently taking other drugs that prolong the QTc including dofetilide, sotalol, quinidine, class Ia antiarrhythmics, class III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron methylate, probucol or tacrolimus. 20. Patients who have failed to experience significant clinical improvement following 3 or more antidepressant trials of adequate duration (at least 6 weeks) and dose (minimal effective doses defined as: fluoxetine, paroxetine, citalopram 20mg; sertraline, fluvoxamine 50mg, escitalopram 10mg, paroxetine CR 25mg, venlafaxine 75mg, duloxetine 60mg, bupropion 150mg, 15mg of mirtazapine, trazodone or nefazodone 300mg). 21. Patients with a QTc > 450msec at the Baseline visit. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Cedars-Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Cedars-Sinai Medical Center | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hamilton Depression Rating Scale | 14 times for an average of 14 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |